Novavax, Inc.
NVAX
$9.06
-$0.29-3.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.18% | 108.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.18% | 108.87% | |||
| Cost of Revenue | -17.31% | 31.11% | |||
| Gross Profit | 142.30% | 133.61% | |||
| SG&A Expenses | 480.38% | -121.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.50% | -15.77% | |||
| Operating Income | -147.91% | 126.38% | |||
| Income Before Tax | -147.51% | 108.82% | |||
| Income Tax Expenses | 161.97% | 157.23% | |||
| Earnings from Continuing Operations | -154.15% | 108.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -154.15% | 108.66% | |||
| EBIT | -147.91% | 126.38% | |||
| EBITDA | -126.74% | 135.80% | |||
| EPS Basic | -153.90% | 108.65% | |||
| Normalized Basic EPS | -110.52% | 138.81% | |||
| EPS Diluted | -153.90% | 108.62% | |||
| Normalized Diluted EPS | -110.69% | 138.19% | |||
| Average Basic Shares Outstanding | 0.46% | 0.11% | |||
| Average Diluted Shares Outstanding | -1.15% | 1.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||